Related Experiment Video
Updated: Jul 19, 2026
10:22
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
Omalizumab: efficacy in allergic disease
1University of California, Los Angeles, CA 90025, USA.
Panminerva Medica
|October 28, 2004
Summary
Omalizumab effectively controls allergic asthma and allergic rhinitis by targeting immunoglobulin E (IgE). This therapy significantly reduces exacerbations and improves patients' quality of life in allergic airway diseases.
Area of Science:
- Immunology
- Allergology
- Pulmonology
Background:
- Asthma and allergic rhinitis significantly impair quality of life.
- These conditions share pathophysiological links, with a strong causal relationship to allergy.
- Immunoglobulin E (IgE) is a key mediator and therapeutic target in allergic airway diseases.
Purpose of the Study:
- To evaluate the efficacy of omalizumab (Xolair) in managing allergic asthma and allergic rhinitis.
- To assess omalizumab's impact on disease control, exacerbations, and quality of life.
Main Methods:
- Three pivotal, placebo-controlled trials were conducted in patients with moderate-to-severe allergic asthma.
- Efficacy was assessed by disease control, exacerbation rates, quality of life, and healthcare utilization.
- Studies also included patients with seasonal/perennial allergic rhinitis and those with concomitant asthma and rhinitis.
Main Results:
- Omalizumab significantly reduced asthma exacerbations and improved quality of life.
- The therapy decreased unscheduled visits, emergency room visits, and hospitalizations.
- Omalizumab improved allergic rhinitis symptoms, reduced rescue medication use, and benefited patients with co-occurring asthma and rhinitis.
Conclusions:
- Omalizumab is an effective treatment for allergic asthma and allergic rhinitis.
- It offers significant disease control and improves quality of life for patients with IgE-mediated allergic airway diseases.
- Omalizumab represents a major clinical advancement in managing allergic conditions.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...